Press Release

Blue Owl Capital Invests up to $1.05 Billion in BridgeBio Pharma

January 17, 2024

Washington, DC – January 17, 2024 – Cooley advised Blue Owl Capital, a top asset manager redefining alternatives, on its strategic investment in BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers. Lawyers Mischi a Marca, Michael Tollini, Addison Pierce and Matt Kong led the interdisciplinary Cooley team advising Blue Owl, which also included patent counseling & prosecution partner Ivor Elrifi, life sciences partner Geoffrey Spolyar and tax partner Xander Lee.

The strategic financing from Blue Owl and Canada Pension Plan Investment Board – through its wholly owned subsidiary CPPIB Credit Investments – provides BridgeBio with up to $1.25 billion in capital.

The investment from Blue Owl consisted of a term loan financing, with $450 million funded at close and an additional $300 million available subject to mutual consent of Blue Owl and Bridge Bio, plus a $500 million royalty financing (of which Blue Owl has provided $300 million of the total commitment), in exchange for future royalties of worldwide net sales of BridgeBio drug acoramidis.

Cooley previously advised Blue Owl on its $140 million investment in XOMA Corporation in December 2023.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.